The Types classification organizes Myelofibrosis drugs into four distinct categories: JAK inhibitors, Immunomodulatory agents, Antifibrotic agents, and Other emerging therapies. JAK inhibitors dominate the market, comprising approximately 70 % of sales; the class includes ruxolitinib and fedratinib, both of which achieve symptom control and spleen volume reduction through selective JAK1/2 blockade. Immunomodulatory agents such as pomalidomide and lenalidomide account for roughly 15 % of revenue, targeting cytokine dysregulation and offering benefit in patients with anemia or thrombocytopenia. Antifibrotic agents—exemplified by PRM‑151 and newer fibrosis‑targeting peptides—represent about 10 % of the market, addressing marrow scarring independent of JAK signaling. The residual 5 % falls under Other emerging therapies, which encompass novel small‑molecule inhibitors, gene‑editing approaches, and combination pipelines currently in Phase II/III trials. Each type contributes uniquely to total market size by fulfilling specific clinical niches, influencing pricing structures, and shaping the pipeline investment landscape. Consequently, shifts in regulatory approvals or clinical trial outcomes within any category can materially reallocate market share and drive strategic realignments among manufacturers.
